PHYSIOMICS PLC 
By
Physiomics plc
The Magdalen Centre The Oxford Science Park Robert Robinson
Avenue Oxford
OX4 4GA UK
Tel 01865 784980
Fax 08701 671931
Physiomics plc (AIM: PYC), the Oxford, UK-based systems
biology company, is pleased to announce its intention to
increase the scope of its offering through the development of
a new modelling service to predict the cardiac toxicity of
drugs. The Directors believe that this new service will be of
particular interest to biotechnology companies looking to
streamline their drug discovery programmes and improve the
success rates of potential drugs and drug combinations. Work
on the new modelling service will commence immediately, using
key calibration data from lab-based studies.
Potential drugs are now routinely screened for their toxicity
in lab-based experiments, but the work is both costly and
time-consuming. Nature Review Drug Discovery (2004) reports
that clinical safety or toxicology problems cause over
one-third of drug discovery failures. Furthermore, The
Toxicologist (2010) reports that the most damaging of such
failures to patients and the most costly to the industry are
those that occur post-approval requiring withdrawal from the
market. Cardiovascular toxicology is the single largest cause
of this.
During 2012 Physiomics intends to develop, validate and
provide as a service, computationally based tools that will
integrate the predictive value of a range of early stage
lab-based studies, to improve the quality of drug discovery
decision making. Although this represents a new area of
physiological application for Physiomics, it will use the
simulation expertise the Company has developed over a
decade.
In order to facilitate this, Physiomics also announces the
appointment of Dr Jonathan Swinton, who today joins the
Company's Scientific Advisory Board. Dr Swinton will be
working closely with the team to develop this new
service.
Dr Swinton trained as a mathematician and researched
computational models of biological processes at the
universities of Oxford, Cambridge and London. Since 2001, he
has worked in pharmaceutical companies large and small. Most
recently he was responsible, at AstraZeneca, for the build of
its systems biology capability. He is currently a director of
the company Deodands Ltd, which provides consultancy in
computational biology to a range of commercial and funding
body clients. He is a Visiting Professor of Computational
Biology at Oxford University.
Physiomics plc
Registered in England and Wales Number 4225086
Registered Office: The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK
Dr Mark Chadwick, CEO of Physiomics, commented: "We are
delighted to be working with Dr Swinton to develop this new
technology. This development represents a key step in our
previously stated strategy to broaden our services beyond
oncology and into new therapeutic areas. We look forward to
launching the new service in due course."
Jonathan Swinton, Deodands Ltd, commented: "These are
exciting times for systems biology in drug discovery as we
see an increasing number of concrete examples of
physiological modelling speeding and simplifying drug
discovery, reducing animal usage and ultimately saving money.
In my judgement cardiac toxicity prediction is one of the
most valuable problems current modelling technology can
address. I believe Physiomics has one of the best track
records in the industry of translating systems biology into
projects of value to its clients, and I am pleased to join
its Scientific Advisory Board to help offer a timely new
service."
Enquiries:
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
Katy Mitchell
+44 (0) 161 832 2174
Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029 ariane.comstive@communications-portfolio.co.uk
About Physiomics plcPhysiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242
million, from the current estimate of around $800 million1.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCell® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002
| distribué par | Ce noodl a été diffusé par Physiomics plc et initialement mise en ligne sur le site http://www.physiomics-plc.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-31 18:15:29 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
| Documents associés | |
| Physiomics to enter new therapeutic area with appointment of SAB member |
